<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font17 { font-size : 17; } .font18 { font-size : 18; } .font21 { font-size : 21; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font21">and </span>
   <span class="font18">with </span>
   <span class="font17">patients </span>
   <span class="font15">hepatitis </span>
   <span class="font15">HBV </span>
   <span class="font14">was </span>
   <span class="font14">for </span>
   <span class="font13">were </span>
   <span class="font13">reactivation </span>
   <span class="font13">viral </span>
   <span class="font13">screening </span>
   <span class="font12">{background </span>
   <span class="font12">haematological </span>
   <span class="font12">(.%) </span>
   <span class="font12">antiviral </span>
   <span class="font12">EAS </span>
   <span class="font12">The </span>
   <span class="font11">margin </span>
   <span class="font11">receiving </span>
   <span class="font11">risk </span>
   <span class="font11">{border-style </span>
   <span class="font11">chronic </span>
   <span class="font11">rate </span>
   <span class="font11">system </span>
   <span class="font11">this </span>
   <span class="font11">those </span>
   <span class="font11">virus </span>
   <span class="font11">prophylaxis </span>
   <span class="font11">px;} </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">had </span>
   <span class="font11">positive </span>
   <span class="font11">alert </span>
   <span class="font11">data </span>
   <span class="font11">HCV </span>
   <span class="font11">from </span>
   <span class="font11">testing </span>
   <span class="font11">not </span>
   <span class="font11">treatment </span>
   <span class="font11">anti-HBc-positive </span>
   <span class="font11">electronic </span>
   <span class="font11">first </span>
   <span class="font11">lymphoma </span>
   <span class="font11">markers </span>
   <span class="font11">patients. </span>
   <span class="font11">study </span>
   <span class="font10">been </span>
   <span class="font10">cases </span>
   <span class="font10">patients, </span>
   <span class="font10">treated </span>
   <span class="font10">HBsAg </span>
   <span class="font10">anti-HBc </span>
   <span class="font10">during </span>
   <span class="font10">myeloid </span>
   <span class="font10">previously </span>
   <span class="font10">these </span>
   <span class="font10">which </span>
   <span class="font10">who </span>
   <span class="font10">according </span>
   <span class="font10">clinical </span>
   <span class="font10">impact </span>
   <span class="font10">infection </span>
   <span class="font10">leukemia </span>
   <span class="font10">number </span>
   <span class="font10">one </span>
   <span class="font10">our </span>
   <span class="font10">prescription </span>
   <span class="font10">px; </span>
   <span class="font10">resolved </span>
   <span class="font10">therapy </span>
   <span class="font10">{font-family </span>
   <span class="font10">DNA </span>
   <span class="font10">This </span>
   <span class="font10">anti-HCV </span>
   <span class="font10">avoided </span>
   <span class="font10">chemotherapy </span>
   <span class="font10">font-size </span>
   <span class="font10">inhibitors </span>
   <span class="font10">malignancies </span>
   <span class="font10">n(%) </span>
   <span class="font10">reported </span>
   <span class="font10">undergoing </span>
   <span class="font10">(). </span>
   <span class="font10">Hepatitis </span>
   <span class="font10">after </span>
   <span class="font10">anti-CD-containing </span>
   <span class="font10">are </span>
   <span class="font10">diagnosed </span>
   <span class="font10">double; </span>
   <span class="font10">estimated </span>
   <span class="font10">including </span>
   <span class="font10">kinase </span>
   <span class="font10">reactivation. </span>
   <span class="font10">reactivations </span>
   <span class="font10">regimens </span>
   <span class="font10">therapy. </span>
   <span class="font10">tyrosine </span>
   <span class="font10">use </span>
   <span class="font10">without </span>
   <span class="font10">year </span>
   <span class="font10">HBsAg, </span>
   <span class="font10">HBsAg-positive </span>
   <span class="font10">However, </span>
   <span class="font10">al. </span>
   <span class="font10">all </span>
   <span class="font10">also </span>
   <span class="font10">anti-HBc, </span>
   <span class="font10">anti-HBs </span>
   <span class="font10">associated </span>
   <span class="font10">baseline </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">data. </span>
   <span class="font10">detectable </span>
   <span class="font10">drugs </span>
   <span class="font10">follicular </span>
   <span class="font10">has </span>
   <span class="font10">have </span>
   <span class="font10">included </span>
   <span class="font10">journal </span>
   <span class="font10">led </span>
   <span class="font10">linked </span>
   <span class="font10">low </span>
   <span class="font10">most </span>
   <span class="font10">multiple </span>
   <span class="font10">myeloma </span>
   <span class="font10">other </span>
   <span class="font10">out </span>
   <span class="font10">panel </span>
   <span class="font10">patient </span>
   <span class="font10">physicians </span>
   <span class="font10">prescribed </span>
   <span class="font10">prophylaxis. </span>
   <span class="font10">received </span>
   <span class="font10">results </span>
   <span class="font10">solid; </span>
   <span class="font10">specific </span>
   <span class="font10">status </span>
   <span class="font10">test </span>
   <span class="font10">than </span>
   <span class="font10">tyrosine-kinase </span>
   <span class="font10">underlying </span>
   <span class="font10">unknown </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(%) </span>
   <span class="font10">(Fig. </span>
   <span class="font10">All </span>
   <span class="font10">Commons </span>
   <span class="font10">Creative </span>
   <span class="font10">Department, </span>
   <span class="font10">EAS. </span>
   <span class="font10">Hepatology </span>
   <span class="font10">March, </span>
   <span class="font10">Number </span>
   <span class="font10">Table </span>
   <span class="font10">Vall </span>
   <span class="font10">although </span>
   <span class="font10">between </span>
   <span class="font10">bold </span>
   <span class="font10">carried </span>
   <span class="font10">case </span>
   <span class="font10">cohort, </span>
   <span class="font10">completed </span>
   <span class="font10">courier; </span>
   <span class="font10">did </span>
   <span class="font10">d’Hebron </span>
   <span class="font10">em; </span>
   <span class="font10">follow-up </span>
   <span class="font10">hematological </span>
   <span class="font10">hepatitis, </span>
   <span class="font10">higher </span>
   <span class="font10">immunosuppressive </span>
   <span class="font10">important </span>
   <span class="font10">individuals </span>
   <span class="font10">infection, </span>
   <span class="font10">large </span>
   <span class="font10">liver </span>
   <span class="font10">lower </span>
   <span class="font10">new </span>
   <span class="font10">only </span>
   <span class="font10">patient’s </span>
   <span class="font10">potential </span>
   <span class="font10">prescribed. </span>
   <span class="font10">prevalence </span>
   <span class="font10">prophylaxis, </span>
   <span class="font10">provided </span>
   <span class="font10">pt;} </span>
   <span class="font10">reactivation, </span>
   <span class="font10">receive </span>
   <span class="font10">tested </span>
   <span class="font10">that </span>
   <span class="font10">using </span>
   <span class="font10">virological </span>
   <span class="font10">within </span>
   <span class="font10">years, </span>
  </p>
 </body>
</html>
